^
Association details:
| Biomarker: | DNMT3A mutation |
|---|---|
| Cancer: | Peripheral T-cell Lymphoma |
| Drug: | Onureg (azacitidine oral) (DNMT inhibitor) |
| Regimen: | CHOP (cyclophosphamide + doxorubicin hydrochloride + prednisone + vincristine) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Multicenter Phase 2 Study of Oral azacitidine (CC-486) plus CHOP as initial treatment for peripheral T-cell lymphoma
Published date:
02/16/2023
Excerpt:
This phase 2 study evaluated oral azacitidine (CC-486), a DNA methyltransferase inhibitor, plus CHOP as initial treatment for PTCL...The frequencies of the TET2, RHOA, DNMT3A, and IDH2 mutations were 76.5%, 41.1%, 23.5% and 23.5%, respectively, with TET2 mutations significantly associated with CR (p=0.007), favorable PFS (p=0.004) and OS (p=0.015), and DNMT3A mutations associated with adverse PFS (p=0.016).
DOI:
https://doi.org/10.1182/blood.2022018254
Trial ID:
